Bravelle (2015-10-23)
· Published by Health Canada · Official notice
Alert type: Drug Recall
Category: Drugs
Issue: Product Safety
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type II
| Lot or serial number | Brand name | Companies | Dosage form | DIN, NPN, DIN-HIM | Strength |
|---|
| Lot H15940B | Bravelle | - Recalling Firm
- Ferring Inc.
- 200 Yorkland Blvd., Suite 800,
- North York
- M2J 5C1
- Ontario
- CANADA
- Marketing Authorization Holder
- Ferring Inc.
- 200 Yorkland Blvd., Suite 800,
- North York
- M2J 5C1
- Ontario
- CANADA
| Poudre lyophilisée stérile pour injection | DIN 02268140 | Urofollitropin 75 IU |
Affected Products
Bravelle
Out of specification result for potency during shelf life testing.
Clinics, hospitals and/or wholesalers in all provinces/territories